PASADENA, Calif.--()--Neumedicines Inc., a privately held company developing therapies based on interleukin-12 (IL-12) as a radiation countermeasure and for the treatment of chemotherapy-induced thrombocytopenia, announces the appointment of David L. Morash to the newly created position of Chief Financial Officer and as a member of the company’s Board of Directors, expanding Board membership to four. Mr. Morash has served as a consultant to the company since 2012, and brings to Neumedicines more than 30 years of executive-level financial and executive experience.
“We look forward to David’s contributions as we advance our business plan, and welcome him to our company and our Board.”
“David is a highly experienced executive with extensive financial, strategic and corporate governance experience. He joins Neumedicines at an important time in our company’s development as we make preparations to initiate clinical testing with HemaMax™ (rHuIL-12) in two cancer indications and expect to receive additional funding from the U.S. Government’s Biomedical Advanced Research & Development Authority (BARDA) to continue development of HemaMax™ as a biodefense radiation medical countermeasure,” said Lena Basile, J.D., Ph.D., President and Chief Executive Officer of Neumedicines. “We look forward to David’s contributions as we advance our business plan, and welcome him to our company and our Board.”
“I’m delighted to join the team at Neumedicines in working to develop and maximize the vast potential of HemaMax™,” said Mr. Morash. “This is indeed an exciting opportunity as Neumedicines prepares to enter a new phase in its corporate development.”
Most recently Mr. Morash was Chief Financial Officer of ISE Corporation, where he was instrumental in several fundraises and in preparing the company for an initial public offering. Prior to ISE, he served as President, Chief Operating Officer and Chief Financial Officer of publicly traded Axesstel, Inc., which he helped to take public. He also served as Executive Vice President and Chief Financial Officer of publicly traded Remec. Earlier in his career, he was Executive Vice President of Wireless Knowledge, a joint venture between Qualcomm and Microsoft, and Executive Vice President and Chief Financial Officer of Safeskin Corporation, a medical device company rated by Forbes as the Best Small Company in the U.S.
Mr. Morash serves on the Board of Directors of California Safe Soil, LLC, a privately held San Diego-based company he co-founded. He holds BA and MBA degrees from Columbia University.
About Neumedicines Inc.
Neumedicines Inc. is developing protein therapeutics that address unmet clinical and societal needs in the fields of oncology, hematology and immunology. The company’s lead product candidate is HemaMax™ (recombinant human interleukin-12, or rHuIL-12), which functions by targeting multiple pathways of hematopoiesis and innate immunity. HemaMax™ is being development as a biodefense radiation medical countermeasure and for indications in oncology, initially for chemotherapy-induced thrombocytopenia. Neumedicines is committed to developing and maximizing the scientific, clinical and commercial potential of its product pipeline. For more information, please visit www.neumedicines.com or follow the Company on Twitter @Neumedicines.